Efficacy of a Home-based Stretching Program on Fibromyalgia Symptoms: a Randomised Controlled Trial

February 12, 2025 updated by: University College of Northern Denmark
This randomised controlled trial will examine the clinical efficacy of a six-week, novel, home-based stretching programme compared to usual care on the effect of symptoms experienced by patients with fibromyalgia.

Study Overview

Status

Recruiting

Study Type

Interventional

Enrollment (Estimated)

58

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Allan Riis, PT. Ph.D.
  • Phone Number: +4572691310
  • Email: alr@ucn.dk

Study Contact Backup

  • Name: Morten P Støve, PT. Msc.
  • Phone Number: 72691004
  • Email: mps@ucn.dk

Study Locations

      • Aalborg, Denmark, 9220
        • Recruiting
        • University College of Northern Denmark
        • Contact:
          • Morten P Støve, PT, Msc.
          • Phone Number: 004522980862
          • Email: mps@ucn.dk
        • Principal Investigator:
          • Morten P Støve, PT, Msc.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • individuals diagnosed with fibromyalgia in accordance with the ACR 2016 diagnostic criteria.
  • individuals diagnosed with chronic non-malignant pain or individuals diagnosed with chronic widespread pain (including fibromyalgia syndrome) are also included when they meet the ACR 2016 diagnostic criteria.

Exclusion Criteria:

  • Non-controlled systemic disorders (such as hypertension, diabetes and coronary insufficiency),
  • neurological conditions that impair alertness or comprehension, musculoskeletal conditions that could compromise assessments (such as nerve root compression or knee joint inflammation),
  • relevant joint disorders (such as severe arthritis, arthroplasty of the hip or knee, and rheumatoid arthritis),
  • recent changes in therapy for fibromyalgia (i.e., within four weeks of baseline).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention
The intervention group receives a home-based rehabilitation program consisting of six weeks of daily static stretching exercises (six minutes a day).
The intervention comprises six weeks of daily static stretching exercises (six minutes a day) in accordance with the recommendation of the American College of Sports Medicine. The intervention is self-administered and consists of two bouts of 30-second bilateral static stretches of the knee flexors, hip abductors, and shoulder elevators.
No Intervention: Control
The control group receives usual care, and no change in treatment is made. Participants will be encouraged to maintain their daily routine but refrain from changing the current pharmacological treatment or initiating new physical exercise practices during the study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Severity of symptoms
Time Frame: Measured at baseline
The Revised Fibromyalgia Impact Questionnaire (FIQ-R) total score
Measured at baseline
Severity of symptoms
Time Frame: Measured following 6 weeks of intervention (primary endpoint)
The Revised Fibromyalgia Impact Questionnaire (FIQ-R) total score
Measured following 6 weeks of intervention (primary endpoint)
Severity of symptoms
Time Frame: Measured 6 months after the primary endpoint (secondary endpoint)
The Revised Fibromyalgia Impact Questionnaire (FIQ-R) total score
Measured 6 months after the primary endpoint (secondary endpoint)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Health-Related Quality of life (HRQL)
Time Frame: Measured at baseline
HRQL is assessed using the Danish version of the Short Form-36
Measured at baseline
Health-Related Quality of life (HRQL)
Time Frame: Measured following 6 weeks of intervention (primary endpoint)
HRQL is assessed using the Danish version of the Short Form-36
Measured following 6 weeks of intervention (primary endpoint)
Health-Related Quality of life (HRQL)
Time Frame: Measured 6 months after the primary endpoint (secondary endpoint)
HRQL is assessed using the Danish version of the Short Form-36
Measured 6 months after the primary endpoint (secondary endpoint)
Self-reported physical activity
Time Frame: Measured at baseline
The International Physical Activity Questionnaire (IPAQ) short form
Measured at baseline
Self-reported physical activity
Time Frame: Measured following 6 weeks of intervention (primary endpoint)
The International Physical Activity Questionnaire (IPAQ) short form
Measured following 6 weeks of intervention (primary endpoint)
Self-reported physical activity
Time Frame: Measured 6 months after the primary endpoint (secondary endpoint)
The International Physical Activity Questionnaire (IPAQ) short form
Measured 6 months after the primary endpoint (secondary endpoint)
Range of motion
Time Frame: Measured at baseline
Passive knee extension range of motion is assessed using the Biodex System 4 Pro isokinetic dynamometer
Measured at baseline
Range of motion
Time Frame: Measured following 6 weeks of intervention (primary endpoint)
Passive knee extension range of motion is assessed using the Biodex System 4 Pro isokinetic dynamometer
Measured following 6 weeks of intervention (primary endpoint)
Pain sensitivity
Time Frame: Measured at baseline
Pain sensitivity expressed as pressure pain thresholds are assessed using a handheld electronic pressure algometer
Measured at baseline
Pain sensitivity
Time Frame: Measured following 6 weeks of intervention (primary endpoint)
Pain sensitivity expressed as pressure pain thresholds are assessed using a handheld electronic pressure algometer
Measured following 6 weeks of intervention (primary endpoint)

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adherence
Time Frame: Measured following 6 weeks of intervention (primary endpoint)
Adherence to the intervention is evaluated by the number of days stretching is performed using the self-reported data from the mHealth app.
Measured following 6 weeks of intervention (primary endpoint)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Lise Eckardt, Pt. Msc, Department of Physiotherapy, University College of Northern Denmark

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 31, 2024

Primary Completion (Estimated)

August 30, 2026

Study Completion (Estimated)

August 30, 2026

Study Registration Dates

First Submitted

June 27, 2024

First Submitted That Met QC Criteria

June 27, 2024

First Posted (Actual)

July 5, 2024

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

February 12, 2025

Last Verified

November 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The study protocol will be published open access. Data is made available upon reasonable request.

IPD Sharing Time Frame

The study protocol will be published open access.

IPD Sharing Access Criteria

Data is made available upon request.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Fibromyalgia

Clinical Trials on Home-based stretching exercises

Subscribe